DRG HYBRID-XL 2020

DRG is proud to announce the launch of two new Anti-Müllerian Hormone (AMH) assays:
AMH ELISA (EIA-6141)
AMH DRG HYBRiD XL® (HYE-5770)


 

Clinical Application:
AMH has been identified as a reliable marker of ovarian reserve that can help predict early ovarian follicle loss and menopause onset.

The level of AMH in the blood can help doctors estimate the number of follicles inside the ovaries, and therefore, the woman’s egg count. Such information is needed, when issues such as family planning, infertility and/or early onset menopause are considered.

AMH levels also reflect the effect of damaging gynecologic surgeries or gonadotoxic treatments such as chemotherapy on ovarian reserve. Furthermore, AMH contributes in the diagnosis of certain diseases such as granulosa cell tumors or polycystic ovary syndrome.


 

AMH Assay Characteristics for Both Assays:
  • Assay Principle: Sandwich ELISA
  • Sample Volume: 25 µL (Serum or Plasma)
  • Components Ready-to-Use
  • Standards Calibrated against NIBSC Code: 16/190
  • Two controls are included
  • Good Correlation to the Gold Standard Method
  • Good Assay Performance (Validated according to CLSI guidelines)
Advantages:
  • Not required samples pre-dilution
  • Not needed shaker or incubator
  • No cross-reactivity to relevant substances
  • Fast assay procedure, short hands-on time
  • Good assay sensitivity, precision and stability
AMH ELISA (EIA-6141)
  • Assay Time: 75 min
  • Assay Range (0.062 – 20.0 ng/mL)
AMH DRG HYBRiD XL®(HYE-5770)
  • Assay Time: 90 min
  • Assay Range (0.40 – 20 ng/mL)

For more information or to buy DRG Hybrid kits, please go to our online store HERE.

DRG International

Search Our Products